Examkin

Question

Difficulty: MediumMonitoring and Treatment Evaluation

A 64-year-old man with metastatic non-small cell lung cancer develops severe diarrhea (up to 10 watery stools daily) and abdominal cramping 4 weeks after initiating pembrolizumab therapy. His symptoms are classified as severe (Grade 3) immune-mediated colitis after infectious etiologies are ruled out and a colonoscopy confirms the diagnosis. He is admitted to the hospital for acute management. Arrange the following steps in the correct evidence-based sequence for the treatment, monitoring, and therapeutic de-escalation of this patient's condition.

  1. 1Permanently discontinue pembrolizumab and initiate high-dose intravenous methylprednisolone.
  2. 2Monitor stool frequency and clinical status closely for 48 to 72 hours to evaluate the efficacy of initial immunosuppression.
  3. 3Administer intravenous infliximab due to a lack of adequate clinical improvement on corticosteroids.
  4. 4Transition to an equivalent dose of oral prednisone once diarrhea improves to Grade 1 (mild) or resolves.
  5. 5Execute a gradual corticosteroid taper over 4 to 6 weeks to prevent a rebound flare of colitis.

Answer

The correct sequence begins with stopping the checkpoint inhibitor and starting high-dose intravenous corticosteroids, followed by a 48 to 72-hour monitoring period. Due to a lack of improvement, a biologic agent (infliximab) is administered, after which the patient is transitioned to oral steroids upon symptom resolution, followed finally by a slow 4 to 6-week taper.
The evidence-based sequence for severe (Grade 3 or 4) immune-mediated colitis starts with permanent discontinuation of the offending agent alongside high-dose intravenous corticosteroids. A critical monitoring window of 48 to 72 hours follows to assess steroid responsiveness. If symptoms are refractory, therapy is escalated to a biologic agent (e.g., infliximab). Once symptoms improve to Grade 1, intravenous steroids are transitioned to oral forms, which must then be tapered very gradually over 4 to 6 weeks to prevent rebound flares.

Step-by-Step Solution

1
Identify the severity and initiate first-line therapy.
Pembrolizumab is discontinued and high-dose intravenous methylprednisolone is started.
Grade 3 immune-mediated colitis requires immediate cessation of the offending agent and profound immunosuppression to halt the autoimmune response.
2
Establish a monitoring timeframe.
The patient is closely observed for 48 to 72 hours.
This is the standard clinical window to determine if the immune-related adverse event is steroid-responsive or steroid-refractory.
3
Escalate therapy for steroid-refractory disease.
Infliximab is administered.
Failure to improve within 48 to 72 hours on high-dose steroids necessitates the addition of a biologic agent like a TNF-alpha inhibitor.
4
De-escalate to oral therapy upon improvement.
Intravenous steroids are switched to oral prednisone.
Once symptoms improve to Grade 1 or baseline, parenteral therapy is no longer required and oral transition facilitates outpatient management.
5
Implement a long-term taper.
Corticosteroids are tapered over 4 to 6 weeks.
Rapid withdrawal of corticosteroids can lead to a severe rebound flare of the immune-mediated adverse event.

Key Concept

Management of severe immune checkpoint inhibitor-mediated colitis involves immediate cessation of the drug, initiation of high-dose corticosteroids, monitoring for 48 to 72 hours, escalation to biologic therapy if refractory, and a subsequent slow corticosteroid taper.
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic